Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

On an ordinary day in Brighton, Dheeresh Turnbull swabbed the inside of his cheek for science. He was healthy, with no ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Jeffrey Wong, MD, discusses the unmet needs in prostate cancer treatment, especially in regard to radiopharmaceuticals.

A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study. Here is a roundup of March 2025 U.S. FDA ...

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

Exercise improved erectile dysfunction compared with standard care among men with prostate cancer, according to study results ...

Even among patients with prostate cancer liver metastasis who have a poor prognosis, elevated ctDNA fraction and tumor suppressor gene loss differentiate survival.

Researchers have unlocked a powerful new way to fight solid tumors using smart immune cells that stay active longer and hit ...